<DOC>
	<DOCNO>NCT00434993</DOCNO>
	<brief_summary>Acute Respiratory Distress Syndrome ( ARDS ) less condition occur prior ARDS , Acute Lung Injury ( ALI ) , medical condition occur severe inflammation increase fluid ( edema ) lung , make hard lung function properly . Patients condition require treatment include use breathe machine ( ventilator ) . The purpose study find whether give albuterol ( drug commonly use asthmatic ) give albuterol patient ALI ARDS make difference long take patient able breath without ventilator .</brief_summary>
	<brief_title>Drug Study Albuterol Treat Acute Lung Injury</brief_title>
	<detailed_description>Aerosolized beta-2 agonist therapy anticipate diminish formation lung edema , enhance clearance lung edema decrease pulmonary inflammation patient acute lung injury . Because beta-2 agonist show reduce permeability induce lung injury , anticipate severity lung injury reduce aerosolized beta-2 agonist therapy . The therapy may work enhance resolution pulmonary edema upregulating alveolar epithelial fluid transport mechanism turn enhance clearance alveolar edema . A reduction severity lung injury quantity alveolar edema result earlier extubation ventilator free day , improved pulmonary oxygen uptake , improve lung compliance . Study design : phase II/III prospective , randomize double-blind , placebo control trial . - In Phase II , patient treat aerosolized albuterol 5.0 mg vs. normal saline ( n=40-50 ) administer every 4 hour 10 day follow randomization 24 hour follow extubation , whichever occur first . The protocol stipulate 5.0 mg dose reduce 2.5 mg patient exceed defined heart rate limit . - In Phase III , 5.0 mg dose use unless evidence dose unacceptable safety profile dose reduction tachycardia occur large fraction patient . In case , low dose 2.5 mg use . - Patients follow 90 day discharge hospital home unassisted breathe whichever occur first .</detailed_description>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Lung Injury</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Must meet follow three criterion within 24hour period : 1 . Acute onset PaO2/FiO2 le equal 300 ( adjustment make altitude appropriate ) 2 . Bilateral infiltrates consistent pulmonary edema frontal chest radiograph 3 . Requirement positive pressure ventilation via endotracheal tube No clinical evidence leftsided cardiac failure account bilateral pulmonary infiltrates Greater 48 hour since inclusion criterion meet Neuromuscular disease impairs ability ventilate without assistance , ( e.g. , cervical spinal cord injury level C5 high spinal cord injury amyotrophic lateral sclerosis , GuillainBarr√© syndrome myasthenia gravis ) Pregnant breastfeed Severe chronic respiratory disease ( i.e. , chronic hypercapnia [ PaCO2 great 45 mmHg ] , chronic hypoxemia [ PaO2 le 55 mmHg FiO2 = 0.21 ] , hospitalization within last 6 month respiratory failure [ PaCO2 great 50 mm Hg and/or PaO2 le 55 mmHg 0.21 FiO2 ] , secondary polycythemia , severe pulmonary hypertension [ mean PAP ( pulmonary artery pressure ) great 40 mmHg ] , ventilator dependency ) Burns great 40 % total body surface area Cancer irreversible disease condition 6month mortality estimate great 50 % Allogeneic bone marrow transplant within 5 year prior study entry Participant , surrogate , physician commit full support ( Exception : participant exclude he/she would receive supportive care except attempt resuscitation cardiac arrest ) Severe chronic liver disease ( ChildPugh score 1115 ) Diffuse alveolar hemorrhage vasculitis Morbid obesity ( great 1kg/cm body weight . ) Unwillingness inability utilize ARDS network 6 ml / kg Predicted Body Weight ( PBW ) ventilation protocol Moribund participant expect survive 24 hour No intent obtain central venous access monitoring intravascular pressure Contraindication aerosolize albuterol ( see Appendix A.8 protocol information ) Daily use ( prior study hospitalization ) inhale beta agonist , corticosteroid , oral leukotriene modifier Unwillingness primary physician discontinue inpatient beta agonist use Acute myocardial infarction acute coronary syndrome within 30 day study entry Severe congestive heart failure ( see Appendix A5 protocol information ) Participation experimental medication trial within 30 day study entry exception ARDSNet pharmaconutrient nutrition trial ( OMEGA ) Heart rate great 85 % maximal predict heart rate ( MHR85 ) calculate MHR85 = 85 % x ( 220age ) Currently receive high frequency ventilation</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Acute Lung Injury</keyword>
	<keyword>Acute Respiratory Distress Syndrome</keyword>
	<keyword>Albuterol</keyword>
	<keyword>Aerosolized</keyword>
	<keyword>Critical Care</keyword>
	<keyword>Ventilator</keyword>
</DOC>